Navigation Links
Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
Date:7/11/2012

SAN DIEGO, July 11, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced an update to the projected timeframe for completion of enrollment of the Light Study, the Contrave® cardiovascular outcomes clinical trial. Orexigen now expects to complete enrollment of patients required for the interim analysis of the Light Study in the first quarter of 2013, potentially reducing by half the original projections.

"2012 has been a year of focused execution at Orexigen in order to conduct the Light Study as quickly as possible," said Michael Narachi, CEO of Orexigen. "The outstanding efforts of our team and our partners have resulted in enrollment rates of the targeted population that are much faster than originally expected."

The primary endpoint of the Light Study is the time to occurrence of major adverse cardiovascular events (MACE) during randomized treatment for Contrave compared to placebo. After approximately 87 MACE have been adjudicated, Orexigen will conduct an interim analysis. Orexigen plans to resubmit the Contrave New Drug Application for approval if in the interim analysis the company is able to exclude a doubling of risk of MACE in patients receiving Contrave compared to placebo.

Orexigen is targeting to enroll a patient population with a 1.5% annualized background rate of MACE. The demographics (age, gender, smoking status, prevalence of cardiovascular disease, diabetes and other co-morbidities) of the patients enrolled into the study to date are in line with the targeted population and the projected MACE rate.

Since initiation of the Light Study at the beginning of June, over 1,500 patients have been enrolled into the study at approximately 100 sites that have been activated thus far. The remaining 200 sites are scheduled to be activated by the end of August. With the revised enrollment projections, and assumin
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
4. NIPTE Will Participate in NIHs Therapeutics for Rare and Neglected Diseases (TRND) Program
5. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
6. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
7. The New Generation of Antibody Therapeutics: Current Status and Future Prospects - Overview
8. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
9. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
10. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
11. Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Atossa Genetics, Inc. (NASDAQ: ATOS ), The Breast ... , Chief Financial Officer & General Counsel, will present at ... 30, 2013, in New York City ... presentation is scheduled to begin at 3:30 p.m. EDT and ... webcast, go to www.atossagenetics.com . For more ...
(Date:5/17/2013)... 17, 2013  Boston Scientific Corporation (NYSE: ... EuroPCR Scientific Program May 21-24 in Paris ... a particularly rich and diversified set of data this ... , M.D., global chief medical officer, Boston Scientific.  "The ... including the NG PROMUS trial, which evaluated our Promus ...
(Date:5/16/2013)... 2013  Nektar Therapeutics, (Nasdaq: NKTR ) President ... , is scheduled to present at the upcoming 2013 UBS ... at the Sheraton New York Hotel on Tuesday, May 21, ... will be accessible via a Webcast through a link posted ... website: http://www.nektar.com . This Webcast will be available for ...
Breaking Medicine Technology:Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
... -- Global Pharm Holdings Group, Inc. (OTCBB: GPHG.OB) ... vertically integrated pharmaceutical company engaged in pharmaceutical related ... subsidiaries in the Anhui, Jilin, and Shandong provinces, ... first quarter ended March 31, 2011. ...
... Diagnostics, a leading developer of quantitative pulmonary imaging software, ... for the evaluation of pulmonary disease including chronic obstructive ... the 2011 International Conference of the American Thoracic Society ... been installed at leading pulmonary centers for validation and ...
Cached Medicine Technology:Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 2Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 3Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 4Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 5Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 6Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 7Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 8Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 9Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 10Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 11VIDA Diagnostics Launches Apollo Pulmonary Analysis Software for Major Lung Disease at American Thoracic Society Meeting 2
(Date:5/18/2013)... 2013 As metal-on-metal hip implant ... country, Bernstein Liebhard LLP notes that a new study ... tissue damage before they experience any pain from a ... Daily will appear in the Journal of Bone & ... screens of their hips. The researchers found tissue ...
(Date:5/18/2013)... Although obesity is associated with an ... obesity and esophageal adenocarcinoma, a type of esophageal cancer, ... As reported on Cancer.gov, last reviewed in January ... likely as those of normal and healthy weight to ... and esophageal cancer is not well understood, it is ...
(Date:5/18/2013)... 2013 The “Sleep Apnea Diagnostic & ... Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, Nasal EPAP, Neurostimulation] ... analyzes and studies the major market drivers, restraints, and ... the World. , Browse , ... Figures , 318 pagesand in-depth TOC ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Adolescents, especially ... known as “Spice” or “K2” are landing in emergency ... to curb this drug epidemic with a new ... marijuana. , According to research from the National Institute ... popular illegal drug among American teenagers. In 2012, 11 ...
(Date:5/18/2013)... DF (PRWEB) May 18, 2013 The ... leading ayurvedic education institution in the West. Program is ... education. , Ayurveda is a healing modality practiced for ... ), it is considered that health begins when an ... profound understanding of their individual needs. Ayurveda aims to ...
Breaking Medicine News(10 mins):Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2
... 18 (HealthDay News) -- A new analysis of existing ... job of treating depression than standard care. Depression ... psychotherapy and antidepressant drugs. According to the analysis, one-third ... treated with four different medications. In addition, among depressed ...
... The BP oil spill in the Gulf of Mexico last ... coastal communities, even in areas where there was no direct ... of Maryland Medical Center and the University of Florida, Gainesville, ... in two fishing communities: Baldwin County, Ala., which had direct ...
... By Maryann Mott HealthDay Reporter , FRIDAY, Feb. ... best friends, but hospital records suggest some pooches feel otherwise. ... States are bitten by dogs, with some bites needing emergency ... hospital admissions caused by dog bites nearly doubled, increasing from ...
... the Children,s Center for Cancer and Blood Diseases and ... today announced a breakthrough discovery in understanding how the ... called CD19-ligand (CD19-L) located on the surface of certain ... of leukemia cells by the immune system. This ...
... , FRIDAY, Feb. 18 (HealthDay News) -- Tapping certain sequences ... German researchers suggest. For example, typing the numbers that ... trigger the feeling of that word in your mind, according ... University of Wurzburg. The researchers created a list of ...
... -- A disease the affects your legs could warn you ... million Americans over the age of 50 have peripheral arterial ... attack, according to the Vascular Disease Foundation and its PAD ... the foundation says. PAD occurs when arteries in the ...
Cached Medicine News:Health News:Peer Support Beats Usual Care for Depression, Analysis Finds 2Health News:Study Finds Widespread Trauma in Wake of BP Oil Spill 2Health News:Rise in Dog Bites Has Experts Concerned 2Health News:Rise in Dog Bites Has Experts Concerned 3Health News:Scientists bioengineer a protein to fight leukemia 2Health News:Using Cell Phones Might Evoke Emotions, Study Suggests 2Health News:Leg Discomfort Might Signal Heart Trouble 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: